Dror Ortho-design, INC

Dror Ortho-Design, Inc. has entered into a securities purchase agreement for a $275,000 private placement of debentures and warrants.

Dror Ortho-Design, Inc. announced a private placement of $250,000 in 0% interest debentures due February 2026, coupled with warrants, to fund general corporate working capital.

Dror Ortho-Design, Inc. announced a private placement of $200,000 in 0% interest debentures and warrants, convertible upon a future public offering, to accredited investors.

Dror Ortho-Design, Inc. completed a $200,000 private placement of 0% interest debentures due September 17, 2025, with attached warrants, to fund general corporate working capital.

Dror Ortho-Design, Inc. announced that its stockholders approved a reverse stock split of its common stock at a special meeting held on June 23, 2025.

Dror Ortho-Design, Inc. has entered into a private placement agreement to raise $200,000 through the sale of 0% interest debentures and warrants, with the debentures convertible into common stock upon a future public offering.

Dror Ortho-Design reports continued development of its orthodontic platform, with reduced R&D spending, but faces significant going concern doubts due to ongoing losses and reliance on financing.

Dror Ortho-Design reports significant operating losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, while also delaying its FDA submission for its novel orthodontic platform.

Pre-revenue aligner developer narrowed its quarterly loss, ended Q3 with $0.24M cash, and entered a $600k 0%-interest debenture financing in November with potential warrant coverage upon a future public offering.

Dror Ortho-Design, an orthodontic R&D company, reported a reduced net loss but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and reliance on external financing.

Dror Ortho-Design, Inc. announced its Q1 2025 financial results, highlighting ongoing research and development of its orthodontic alignment platform and the necessity for additional funding to sustain operations.

Dror Ortho-Design reported increased research and development expenses and a net loss for the third quarter of 2024, alongside a significant increase in share-based compensation expenses.

Dror Ortho-Design, a development-stage company, announced FDA 510(k) clearance for its ZSmile orthodontic platform, despite ongoing operating losses and significant liquidity challenges.

Dror Ortho-Design's 2024 annual report reveals ongoing losses as the company invests in its ZSmile platform, a novel approach to teeth alignment.

Dror Ortho-Design files an amendment to its annual report to correct a filing error regarding the registration of its common stock and to disclose an additional issuance of unregistered securities.

Dror Ortho-Design's 10-K filing details its capital structure, including common and preferred stock, warrants, and options, while outlining its innovative approach to the orthodontic market.

Yehuda Englander, a director at Dror Ortho-Design, Inc., acquired 9,597,675 stock options on June 17, 2024.

Moshe Shvets, Chief Technology Officer of Dror Ortho-Design, Inc., reports the acquisition of stock options.

Eliyahu Haddad, CEO of Dror Ortho-Design, Inc., reports the acquisition of 95,965,715 stock options on June 17, 2024.

Chaim Hurvitz, a director at Dror Ortho-Design, Inc., acquired 21,122,239 stock options on June 17, 2024.

Dror Ortho-Design, Inc. has filed an amended definitive proxy statement, rescheduling its Special Meeting to June 23, 2025, to seek stockholder approval for a reverse stock split aimed at increasing its share price and facilitating a potential uplisting to NYSE American.

Dror Ortho-Design is asking stockholders to approve a reverse stock split at its special meeting on June 13, 2025, to increase its stock price and potentially uplist to the NYSE American.

Dror Ortho-Design, a pre-revenue medical device company, is pursuing a public offering of up to 3.6 million shares and prefunded warrants to raise $13 million, alongside a 1-for-550 reverse stock split, while facing significant financial challenges and a going concern doubt.

Dror Ortho-Design, Inc., a development-stage company, filed an amended S-1 registration statement to offer up to 2,020,203 shares of common stock and warrants, aiming to raise approximately $8.9 million for working capital and general corporate purposes, while facing significant operating losses and a going concern warning.

Dror Ortho-Design, Inc., a development-stage company with no current revenues, has filed an S-1 registration statement to offer common stock and warrants, seeking to raise capital for its proprietary AI-based ZSmile orthodontic platform while facing substantial doubt about its ability to continue as a going concern.

Dror Ortho-Design, Inc. files an amendment to its Form S-1 registration statement to register the resale of over 2.3 billion shares of common stock by selling securityholders.

Dror Ortho-Design, Inc. files an amendment to its S-1 registration statement to register the resale of over 2.3 billion shares of common stock by selling securityholders.

Dror Ortho-Design registers for the resale of over 2.3 billion shares of common stock by selling securityholders after completing a share exchange and private placement.

Congregation Ahavas Tzdokah Vchesed Inc. has filed an amendment to its Schedule 13D, reporting a decrease in its beneficial ownership of DROR ORTHO-DESIGN INC. and a shift in its investment intent from influencing control to solely investment purposes.

AIGH Capital Management and Orin Hirschman jointly report beneficial ownership of 9.9% and 9.1% respectively in Dror Ortho-Design, Inc. common stock.

Congregation Ahavas Tzdokah Vchesed Inc. has reported a beneficial ownership of 6.444% of DROR ORTHO-DESIGN INC.'s common stock, totaling 61,667,440 shares, as of November 14, 2024.

AIGH Capital Management, LLC and Orin Hirschman have jointly filed an amended Schedule 13G, reaffirming their beneficial ownership of 9.9% of Dror Ortho-Design, Inc.'s common stock.